CNBC Stock Blog

Where to Invest for the Next 10-20 Years: Strategist

Markets started February on an optimistic note, after logging the worst month in over a year, in January. Will the trend continue throughout this month? Fritz Meyer, senior market analyst at InvescoAIM, and Ronald Weiner, president and chief executive of RDM Financial Group, shared their market outlooks.

“I’m not surprised and I'm not concerned at the market’s correction after all,” Meyer told CNBC. “We’re up 60 percent from the bottom, so what do you expect?”

Checking Market Pulse

Meyer explained that the factors that have spooked the market haven’t changed the fundamental picture, which is a strong economic and earnings recovery.

“Last week, for example, the ECRI* said their leading index suggests to them that a V-shape recovery is coming into focus, and if we get $80 and $95 a share this year and next year on the S&P 500, then there’s a lot of further room for stocks to move higher,” he said.
*(Economic Cycle Research Institute)

In the meantime, Weiner said he remains concerned about the market.

“If the U.S. was looked at as a corporation, the board of directors are really out of sync with each other,” he said. “We’re concerned about the government trying to fix things. Regulation is not going to be great and the higher taxes are not going to be great.”

He projected that the global economy is going to be what eventually bails out the U.S. economy.

“There will be bumps in the road everywhere,” he said. “If you look at the emerging markets, they don’t have all the problems we have.”

“As much as 2 billion people are going to enter the middle class in the next 20 years and that’s the place to be—or be in the companies that sell to the next 10 to 20 years.”

More Market Intelligence:

CNBC Data Pages:

CNBC Slideshows:


CNBC's Companies in the News:


  • Toyota to Restart US Plants; Confident on Fix

Goldman Sachs

  • Goldman CEO May Get $100 Million Bonus: Report


  • UBS Shares Hit by Swiss Minister 'Fail' Comments

Boston Scientific

Johnson & Johnson

  • Boston Scientific Settles Stent Suit for $1.73 Billion


No immediate information was available for Meyer or Weiner.